Predictive medicine and clinical nephrology


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Обсуждаются перспективы внедрения принципов персонифицированной медицины в клиническую нефрологию.

Негізгі сөздер

Толық мәтін

Рұқсат жабық

Авторлар туралы

N. Moukhin

Email: moukhin-nephro@yandex.ru

Әдебиет тізімі

  1. Siena S., Sartore-Bianchi A., Di Nicolantonio F. et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009;101(19): 1308—1324.
  2. Cappuzzo F., Hirsch F.R., Rossi E. et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005; 97(9): 643-655.
  3. Garcia-Donas J., Esteban E., Leandro-García L.J. et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 2011; 12(12): 1143-1150.
  4. Rini B.I., Cohen D.P., Lu D.R. et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2011; 103(9): 763-773.
  5. Lampreabe I., Gainza de los Rios F.J., Arrieta Gutiérrez A. et al. Toward personalized medicine in renal transplantation. Transplant Proc. 2010; 42(8): 2864-2867.
  6. Игнатова М.С., Шатохина О.В. Диагностика и лечение нефротического синдрома у детей. М., МИА, 2009.
  7. Fuchshuber A., Jean G., Gribouval A. et al. Congenital nephrotic syndrome of the Finnish-type: linkage to the locus in a non-Finnish population. Pediatr Nephrol. 1996; 10: 135-138.
  8. Caridi G., Perfumo F, Ghiggeri G.M. NPHS2 (Podocin) mutations in nephrotic syndrome. Clinical spectrum and fine mechanisms. Pediatr Res. 2005; 57(5 Pt 2):54R-61R.
  9. Hildebrandt F., Heeringa S.F. Specific podocin mutations determine age of onset of nephrotic syndrome all the way into adult life. Kidney Int. 2009; 75(7): 669-671.
  10. Sanchez-Ares M., Garcia-Vidal M., Antucho E.E. et al. A novel mutation, outside of the candidate region for diagnosis, in the inverted formin 2 gene can cause focal segmental glomerulosclerosis. Kidney Int. 2012 Sep 12. doi: 10.1038/ki.2012.325. [Epub ahead of print]
  11. Barua M., Brown E.J., Charoonratana V.T. et al. Mutations in the INF2 gene account for a significant proportion of familial but not sporadic focal and segmental glomerulosclerosis. Kidney Int. 2012 Sep 26. doi: 10.1038/ ki.2012.349. [Epub ahead of print]
  12. Eng C.M., Germain D.P., Banikazemi M. et al. Fabru disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med 2006; 8(9): 539-548.
  13. Eng C.M., Fletcher J., Wilcox W.R. et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis 2007; 30(2): 184-192.
  14. Nakao S., Kodama C., Takenaka T. et al. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a “renal variant” phenotype. Kidney Int. 2003; 64(3): 801-807.
  15. Kotanko P., Kramar R., Devrnja D. et al. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J. Am. Soc. Nephrol. 2004; 15(5): 1323-1329.
  16. Ichinose M., Nakayama M., Ohashi T. et al. Significance of screening for Fabry disease among male dialysis patients. Clin. Exp. Nephrol. 2005; 9(3): 228-232.
  17. Fogo A.B., Bostad L., Svarstad E. et al. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISFGN). Nephrol. Dial. Transplant. 2010; 25(7): 2168-2177.
  18. Germain D.P., Waldek S., Banikazemi M. et al. Sustained, long-term renal stabilization after 54 moths of agalsidase therapy in patients with Fabry disease. J. Am. Soc. Nephrol. 2007; 18: 1547-1557.
  19. Banikazemi M., Bultas J. Waldeck S. et al. Agalsidase-beta therapy for advanced Fabry disease. A randomized trial. Ann. Intern. Med. 2007; 146: 77-86.
  20. Фомин В.В., Пулин А.А., Рамеев В.В. и др. Болезнь Фабри с поражением почек с протеинурией и гипертрофической кардиомиопатией, ошибочно интерпретированная как хронический гломерулонефрит при пурпуре Шенлейна-Геноха. Клин. нефрология. 2010; 5: 70-78.
  21. Benetti E., Caridi G., Malaventura C. et al. A novel WT1 gene mutation in a three-generation family with progressive isolated focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 2010;5(4): 698-702.
  22. Orloff M.S., Iyengar S.K., Winkler C.A. et al. Variants in the Wilms' tumor gene are associated with focal segmental glomerulosclerosis in the African American population. Physiol. Genomics. 2005; 21(2): 212-221.
  23. Schlöndorff J., Del Camino D., Carrasquillo R. et al. TRPC6 mutations associated with focal segmental glomerulosclerosis cause constitutive activation of NFAT-dependent transcription. Am. J. Physiol. Cell. Physiol. 2009; 296(3): C558-C569.
  24. Kopp J.B., Smith M.W., Nelson G.W. et al. MYH9 is a maaor-effect risk gene for focal segmental glomerulosclerosis. Nat. Genet. 2008; 40(10): 1175-1184.
  25. Freedman B.I, Hicks P.J., Bostrom M.A. et al. Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are strongly associated with endstage renal disease historically attributed to hypertension in African Americans. Kidney Int. 2009; 75(7): 736-745.
  26. Freedman B.I., Hicks P.J., Bostrom M.A. et al. Non-muscle myosin heavy chain 9 gene MYH9 associations in African Americans with clinically diagnosed type 2 diabetes mellitus-associated ESRD. Nephrol. Dial. Transplant. 2009; 24(11): 3366-3371.
  27. Kopp J.B., Winkler C.A., Nelson G.W. MYH9 genetic variants associated with glomerular disease: what is the role for genetic testing? Semin Nephrol. 2010; 30(4): 409-417.
  28. Johnstone D.B., Zhang J., George B. et al. Podocyte-specific deletion of Myh9 encoding nonmuscle myosin heavy chain 2A predisposes mice to glomerulopathy. Mol Cell Biol. 2011; 31(10): 2162-2170.
  29. Cheng W., Zhou X., Zhu L. et al. Polymorphisms in the nonmuscle myosin heavy chain 9 gene (MYH9) are associated with the progression of IgA nephropathy in Chinese. Nephrol Dial Transplant. 2011; 26(8): 2544-2549.
  30. Löwik M.M., Groenen P.J., Levtchenko EN. Molecular genetic analysis of podocyte genes in focal segmental glomerulosclerosis - a review. Eur. J. Pediatr. 2009; 168(11): 1291-1304.
  31. Franceschini N., North K.E., Kopp J.B. et al. NPHS2 gene, nephrotic syndrome and focal segmental glomerulosclerosis: a HuGE review. Genet. Med. 2006; 8(2): 63-75.
  32. Brown E.J., Schlöndorff J.S., Becker D.J. et al. Mutations in theformin gene INF2 cause focal segmental glomerulosclerosis. Nat. Genet. 2010; 42(1): 72-76.
  33. Cohen C.D., Calvaresi N., Armelloni S. et al. CD20-positive infiltrates in human membranous glomerulonephritis. J Nephrol. 2005; 18: 328-333.
  34. Пулин А.А., Горностаева Е.Ю., Рощупкина С.В. и др. Эффективность лечения ритуксимабом больного идиопатической мембранозной нефропатией, резистентной к стандартной иммуносупрессивной терапии. Клин. нефрология. 2011; 5: 72-77.
  35. Ruggenenti P., Cravedi P., Sghirlanzoni M.C. et al. Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. Clin J Am Soc Nephrol. 2008; 3: 1652-1659.
  36. Мухин Н.А., Семенкова Е.Н., Кривошеев О.Г., Новиков П.И. Применение ритуксимаба при тяжелых АНЦА-ассоциированных системных васкулитах. Клиническая нефрология. 2010; 2: 40-45.
  37. Chen C.C., Geurts A.M., Jacob H.J. et al. Heterozygous knockout of transforming growth factor-ß1 protects Dahl S rats against high salt-induced renal injury. Physiol Genomics. 2012 Dec 18. [Epub ahead of print].

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML